Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2017/01/07 03:06:04」(JST)

wiki en

Eszopiclone, marketed by Sunovion under the brand-name Lunesta, is a nonbenzodiazepine hypnotic which is slightly effective for insomnia.^[2] Eszopiclone is the active dextrorotatory stereoisomer of zopiclone, and belongs to the class of drugs known as cyclopyrrolones.

Eszopiclone (Lunesta) along with other "Z-drugs" including zolpidem (Ambien), zaleplon (Sonata) are the most commonly prescribed sedative hypnotics in the United States. Eszopiclone is not marketed in the European Union following a 2009 decision by the EMA denying it new active substance status,^[3] in which it ruled that eszopiclone was too similar to zopiclone to be considered a new patentable product.^[4]

Eszopiclone is now available in a generic form in the United States as of May 2014. On May 15, 2014, the USFDA asked that the starting dose of Eszopiclone (Lunesta) be lowered from 2 milligrams to 1 milligram after it was observed in a study that even 8 hours after taking the drug at night, some patients were not able to cope with their next-day activities like driving and other activities that require full alertness.^[5]

Medical uses

Eszopiclone is slightly effective in the treatment of insomnia where difficulty in falling asleep is the primary complaint.^[2] Kirsch et al. found the benefit over placebo to be of questionable clinical significance.^[2] Although the drug effect and the placebo response were rather small and of questionable clinical importance, the two together produce a reasonably large clinical response.^[2] It is not recommended for chronic use in the elderly.^[6]

Elderly

Sedative hypnotic drugs including eszopiclone are more commonly prescribed to the elderly than to younger patients despite benefits of medication being generally unimpressive. Care should be taken in choosing an appropriate hypnotic drug and if drug therapy is initiated it should be initiated at the lowest possible dose to minimise side effects.^[7] An extensive review of the medical literature regarding the management of insomnia and the elderly found that there is considerable evidence of the effectiveness and durability of non-drug treatments for insomnia in adults of all ages and that these interventions are underutilized. Compared with the benzodiazepines, the nonbenzodiazepine sedative-hypnotics, including eszopiclone appeared to offer few, if any, significant clinical advantages in efficacy or tolerability in elderly persons. It was found that newer agents with novel mechanisms of action and improved safety profiles, such as the melatonin agonists, hold promise for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and has traditionally been discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of these agents remain to be determined. It was concluded that more research is needed to evaluate the long-term effects of treatment and the most appropriate management strategy for elderly persons with chronic insomnia.^[8]

Adverse effects

Eszopiclone has fewer anticholinergic side effects than racemic zopiclone.^[9] The following side effects may occur from usage of eszopiclone (Lunesta):^[10]

Common side effects can include:

unpleasant bitter or metallic taste
headaches
chest pain
cold-like symptoms
pain
dry mouth
daytime drowsiness
lightheadedness
dizziness
upset stomach
decreased sexual desire
painful menstruation (periods)
heartburn
Sedation, drowsiness, and sleepiness

Less common side effects can include:

rashes
itching
incoordination
swelling of the hands, feet, ankles, or lower legs
painful or frequent urination
back pain

neuropsychiatric adverse effects reported include:

aggressive behavior
confusion
agitation
auditory and visual hallucinations
worsening of depression
suicidal thoughts
depersonalisation
amnesia

If a person does not sleep immediately after taking eszopiclone or if they get up shortly after taking the medication they may experience dizziness, lightheadedness, hallucinations (seeing things or hearing voices that are not there), as well as problems with coordination and memory.

Dependence

In the United States Eszopiclone is a schedule IV controlled substance under the Controlled Substances Act. Use of benzodiazepines and similar benzodiazepine-like drugs such as eszopiclone may lead to physical and psychological dependence. The risk of abuse and dependence increases with the dose and duration of usage and concomitant use of other psychoactive drugs. The risk is also greater in patients with a history of alcohol abuse or other drug abuse or history of psychiatric disorders. Tolerance may develop after repeated use of benzodiazepines and benzodiazepine-like drugs for a few weeks. Eszopiclone was studied for up to 6 months in a group of patients which showed no signs of tolerance or dependence in a study funded and carried out by Sepracor.^[11]

Abuse

A study of abuse potential of eszopiclone found that in persons with a known history of benzodiazepine abuse, eszopiclone at doses of 6 and 12 mg produced effects similar to those of diazepam 20 mg. The study found that at these doses which are two or more times greater than the maximum recommended doses, a dose-related increase in reports of amnesia, sedation, sleepiness, and hallucinations was observed for both eszopiclone (Lunesta) as well as for diazepam (Valium).^[10]

Overdose

According to the U.S. Prescribing Information, overdoses of eszopiclone up to 90 times the recommended dose have been reported in which the patient fully recovered. According to the May 2014 edition of the official U.S. Prescribing Information, fatalities have been reported only in cases in which eszopliclone was combined with other drugs or alcohol.^[12]

Texas poison control centers reported that during 2005–2006 there were 525 total eszopiclone overdoses recorded in the state of Texas, the majority of which were intentional suicide attempts.^[13]

If consumed within the last hour, eszopiclone overdose can be treated with the administration of activated charcoal or via gastric lavage.^[14]

Pharmacology

Eszopiclone acts on benzodiazepine binding site situated on GABA_A neurons as an agonist.^[15] Eszopiclone is rapidly absorbed after oral administration, with serum levels peaking between .45 and 1.3 hours.^[16] The elimination half-life of eszopiclone is approximately 6 hours and it is extensively metabolized by oxidation and demethylation. Approximately 52% to 59% of a dose is weakly bound to plasma protein. Cytochrome P450 (CYP) isozymes CYP3A4 and CYP2E1 are involved in the biotransformation of eszopiclone; thus, drugs that induce or inhibit these CYP isozymes may affect the metabolism of eszopiclone. Less than 10% of the orally administered dose is excreted in the urine as racemic zopiclone.^[17] In terms of benzodiazepine receptor binding and relevant potency, 3 mg of eszopiclone is equivalent to 10 mg of diazepam.^[18]

Controversy

In a 2009 article in the New England Journal of Medicine, "Lost in Transmission — FDA Drug Information That Never Reaches Clinicians", it was reported that the largest of three Lunesta trials found that compared to placebo Lunesta "was superior to placebo" while it only shortened initial time falling asleep by 15 minutes on average. "Clinicians who are interested in the drug’s efficacy cannot find efficacy information in the label: it states only that Lunesta is superior to placebo. The FDA’s medical review provides efficacy data, albeit not until page 306 of the 403-page document. In the longest, largest phase 3 trial, patients in the Lunesta group reported falling asleep an average of 15 minutes faster and sleeping an average of 37 minutes longer than those in the placebo group. However, on average, Lunesta patients still met criteria for insomnia and reported no clinically meaningful improvement in next-day alertness or functioning."^[19]

Availability in Europe

On September 11, 2007, Sepracor signed a marketing deal with British pharmaceutical company GlaxoSmithKline for the rights to sell Eszopiclone (under the name Lunivia rather than Lunesta) in Europe.^[20] Sepracor was expected to receive approximately 155 million dollars if the deal went through.^[20] In 2008 Sepracor submitted an application to the EMA (the European Union's equivalent to the U.S. FDA) for authorization to market the drug in the EU, and initially received a favourable response.^[21] However, Sepracor withdrew its authorization application in 2009 after the EMA stated it would not be granting eszopiclone 'new active substance' status, as it was essentially pharmacologically and therapeutically too similar to zopiclone to be considered a new patentable product.^[22] Since zopiclone's patent has expired, this ruling would have allowed rival companies to also legally produce cheaper generic versions of eszopiclone for the European market.^[23] As of November 2012^[update], Sepracor has not resubmitted its authorization application and Lunesta/Lunivia is not available in Europe. The deal with GSK fell through, and GSK instead launched a $3.3 billion deal to market Actelion's Almorexant sleeping tablet, which entered stage three medical trials before development was abandoned due to side effects.

References

^ WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.
^ ^a ^b ^c ^d Huedo-Medina, TB; Kirsch, I; Middlemass, J; Klonizakis, M; Siriwardena, AN (Dec 17, 2012). "Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration.". BMJ (Clinical research ed.). 345: e8343. doi:10.1136/bmj.e8343. PMC 3544552. PMID 23248080.
^ Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone) – EMA, 15 May 2009
^ End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight – CBS/BNet, 13 Jun 2009
^ FDA requiring lower starting dose for drug Eszopiclone (Lunesta)
^ American Geriatrics Society 2012 Beers Criteria Update Expert, Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.". Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677. PMID 22376048.
^ Tariq SH, Pulisetty S (February 2008). "Pharmacotherapy for insomnia". Clin Geriatr Med. 24 (1): 93–105, vii. doi:10.1016/j.cger.2007.08.009. PMID 18035234.
^ Bain KT (June 2006). "Management of chronic insomnia in elderly persons". Am J Geriatr Pharmacother. 4 (2): 168–92. doi:10.1016/j.amjopharm.2006.06.006. PMID 16860264.
^ Patil PA, Kothekar MA (October 2006). "Development of safer molecules through chirality". Indian J Med Sci. 60 (10): 427–37. doi:10.4103/0019-5359.27676. PMID 17006031.
^ ^a ^b rxlist. "Lunesta". Retrieved 22 March 2008.
^ Brielmaier BD (January 2006). "Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent". Proc (Bayl Univ Med Cent). 19 (1): 54–9. PMC 1325284. PMID 16424933.
^ "Lunesta Prescribing Information at Drugs@FDA" (PDF). Retrieved 2014-05-22.
^ Forrester MB (October 2007). "Eszopiclone ingestions reported to Texas poison control centers, 2005 2006". Hum Exp Toxicol. 26 (10): 795–800. doi:10.1177/0960327107084045. PMID 18025051.
^ (( cite web | url = http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Informationforlicenceapplicants/Guidance/OverdosesectionsofSPCs/Genericoverdosesections/Zopiclone/index.htm ))
^ Jufe GS (July–August 2007). "[New hypnotics: perspectives from sleep physiology]". Vertex. 18 (74): 294–9. PMID 18265473.
^ Halas CJ (January 1, 2006). "Eszopiclone". Am J Health Syst Pharm. 63 (1): 41–8. doi:10.2146/ajhp050357. PMID 16373464.
^ Najib J (April 2006). "Eszopiclone, a non-benzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia". Clin Ther. 28 (4): 491–516. doi:10.1016/j.clinthera.2006.04.014. PMID 16750462.
^ Professor Ashton (April 2007). "BENZODIAZEPINE EQUIVALENCE TABLE". Retrieved 21 March 2008.
^ Schwartz, Lisa M.; Steven Woloshin (October 2009). "Lost in Transmission — FDA Drug Information That Never Reaches Clinicians" (Online). New England Journal of Medicine. NEJM.org. 361 (18): 1717–1720. doi:10.1056/NEJMp0907708. PMID 19846841. Retrieved 2010-12-06.
^ ^a ^b GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia
^ COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USEm SUMMARY OF POSITIVE OPINION for LUNIVIA – European Medicines Agency/Committee for Medicinal Products for Human Use, 23 Oct 2010
^ Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone) – European Medicines Agency, 15 May 2009
^ Data exclusivity and definition of a new active substance: suspension of generic escitalopram-containing medicines by CHMP – Bird and Bird Commercial Law 23 Apr 2010

External links

National Institute of Health – Medline Plus – (Eszopiclone)
Eszopiclone labeling text (PDF)
Sepracor.com
Lunesta.com

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人に生じる不眠症の治療 treatment of insomnia in adults
2. 成人の単極性うつ病：抗不安薬による治療 unipolar depression in adults treatment with anxiolytics
3. 小児や青年の不眠症への薬物療法：エビデンスに基づいた治療法 pharmacotherapy for insomnia in children and adolescents a rational approach
4. 小児における不眠の問題をもたらす医学的障害 medical disorders resulting in problem sleeplessness in children
5. 持続的気道陽圧（CPAP）のアドヒアランス adherence with continuous positive airway pressure cpap

English Journal

GABAA receptor positive allosteric modulators modify the abuse-related behavioral and neurochemical effects of methamphetamine in rhesus monkeys.

Berro LF1, Andersen ML1, Tufik S2, Howell LL3.
Neuropharmacology.Neuropharmacology.2017 Sep 1;123:299-309. doi: 10.1016/j.neuropharm.2017.05.010. Epub 2017 May 8.
PMID 28495376

Response to a combination of oxygen and a hypnotic as treatment for obstructive sleep apnoea is predicted by a patient's therapeutic CPAP requirement.

Landry SA1,2, Joosten SA3,4,5, Sands SA6, White DP6, Malhotra A6,7, Wellman A6, Hamilton GS3,4,5, Edwards BA1,2,6.
Respirology (Carlton, Vic.).Respirology.2017 Aug;22(6):1219-1224. doi: 10.1111/resp.13044. Epub 2017 Apr 13.
PMID 28409851

Insomnia: Pharmacologic Therapy.

Matheson E1, Hainer BL1.
American family physician.Am Fam Physician.2017 Jul 1;96(1):29-35.
PMID 28671376

Japanese Journal

特別講演エスゾピクロンによる不眠症治療 (第29回不眠研究発表会)

不眠研究, 67-78, 2014
NAID 40020257222

Eszopicloneとcomorbid insomnia (特集 Eszopiclone : 基礎と臨床)

精神科 22(2), 197-202, 2013-02
NAID 40019582127

Eszopicloneのうつ病に伴う不眠への効果 (特集 Eszopiclone : 基礎と臨床)

精神科 22(2), 191-196, 2013-02
NAID 40019582116

Related Pictures

JustSleep (Eszopiclone) File:Eszopiclone-3D-vdW.png Eszopiclone Tablets الإسم العلمي eszopiclone File:Eszopiclone-2D-skeletal.png Eszopiclone (Fulnite) - 1mg (10 Tablets) Fulnite (Eszopiclone)

★リンクテーブル★

リンク元

「エスゾピクロン」

Eszopiclone
Clinical data
Trade names	Lunesta
AHFS/Drugs.com	Monograph
MedlinePlus	a605009
License data	US FDA: Eszopiclone;
Pregnancy; category	US: C (Risk not ruled out); ;
Dependence; liability	Moderate
Routes of; administration	Oral (tablets)
ATC code	N05CF04 (WHO)
Legal status
Legal status	US: Schedule IV;
Pharmacokinetic data
Protein binding	52–59%
Metabolism	Hepatic oxidation and demethylation (CYP3A4 and CYP2E1-mediated)
Biological half-life	6 hours
Excretion	Renal
Identifiers
	IUPAC name (S)-(+)-6-(5-Chloro-2-pyridinyl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl-4-methyl-1-piperazinecarboxylate;
CAS Number	138729-47-2
PubChem (CID)	969472
IUPHAR/BPS	7429
DrugBank	DB00402
ChemSpider	839530
UNII	UZX80K71OE
KEGG	D02624
ChEBI	CHEBI:53760
ChEMBL	CHEMBL1522
ECHA InfoCard	100.149.304
Chemical and physical data
Formula	C17H17ClN6O3
Molar mass	388.808 g/mol
3D model (Jmol)	Interactive image
	SMILES O=C(O[C@H]3c1nccnc1C(=O)N3c2ncc(Cl)cc2)N4CCN(C)CC4 ;
	InChI InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3/t16-/m0/s1 ; Key:GBBSUAFBMRNDJC-INIZCTEOSA-N ;
(verify)

　　[★]

英: eszopiclone
商: ルネスタ

参考

http://rokushin.blog.so-net.ne.jp/2012-05-18

[1] WHO International Working Group for Drug Statistics Methodology (August 27, 2008). "ATC/DDD Classification (FINAL): New ATC 5th level codes". WHO Collaborating Centre for Drug Statistics Methodology. Archived from the original on 2008-05-06. Retrieved 2008-09-05.

[TB2012-2] Huedo-Medina, TB; Kirsch, I; Middlemass, J; Klonizakis, M; Siriwardena, AN (Dec 17, 2012). "Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration.". BMJ (Clinical research ed.). 345: e8343. doi:10.1136/bmj.e8343. PMC 3544552. PMID 23248080.

[3] Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone) – EMA, 15 May 2009

[CBS-4] End of Sepracor-GSK Deal Raises Question in Lunesta Patent Fight – CBS/BNet, 13 Jun 2009

[5] FDA requiring lower starting dose for drug Eszopiclone (Lunesta)

[6] American Geriatrics Society 2012 Beers Criteria Update Expert, Panel (April 2012). "American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults.". Journal of the American Geriatrics Society. 60 (4): 616–31. doi:10.1111/j.1532-5415.2012.03923.x. PMC 3571677. PMID 22376048.

[7] Tariq SH, Pulisetty S (February 2008). "Pharmacotherapy for insomnia". Clin Geriatr Med. 24 (1): 93–105, vii. doi:10.1016/j.cger.2007.08.009. PMID 18035234.

[8] Bain KT (June 2006). "Management of chronic insomnia in elderly persons". Am J Geriatr Pharmacother. 4 (2): 168–92. doi:10.1016/j.amjopharm.2006.06.006. PMID 16860264.

[9] Patil PA, Kothekar MA (October 2006). "Development of safer molecules through chirality". Indian J Med Sci. 60 (10): 427–37. doi:10.4103/0019-5359.27676. PMID 17006031.

[lunestasefxab-10] rxlist. "Lunesta". Retrieved 22 March 2008.

[11] Brielmaier BD (January 2006). "Eszopiclone (Lunesta): a new nonbenzodiazepine hypnotic agent". Proc (Bayl Univ Med Cent). 19 (1): 54–9. PMC 1325284. PMID 16424933.

[12] "Lunesta Prescribing Information at Drugs@FDA" (PDF). Retrieved 2014-05-22.

[13] Forrester MB (October 2007). "Eszopiclone ingestions reported to Texas poison control centers, 2005 2006". Hum Exp Toxicol. 26 (10): 795–800. doi:10.1177/0960327107084045. PMID 18025051.

[14] (( cite web | url = http://www.mhra.gov.uk/Howweregulate/Medicines/Licensingofmedicines/Informationforlicenceapplicants/Guidance/OverdosesectionsofSPCs/Genericoverdosesections/Zopiclone/index.htm ))

[15] Jufe GS (July–August 2007). "[New hypnotics: perspectives from sleep physiology]". Vertex. 18 (74): 294–9. PMID 18265473.

[16] Halas CJ (January 1, 2006). "Eszopiclone". Am J Health Syst Pharm. 63 (1): 41–8. doi:10.2146/ajhp050357. PMID 16373464.

[17] Najib J (April 2006). "Eszopiclone, a non-benzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia". Clin Ther. 28 (4): 491–516. doi:10.1016/j.clinthera.2006.04.014. PMID 16750462.

[18] Professor Ashton (April 2007). "BENZODIAZEPINE EQUIVALENCE TABLE". Retrieved 21 March 2008.

[19] Schwartz, Lisa M.; Steven Woloshin (October 2009). "Lost in Transmission — FDA Drug Information That Never Reaches Clinicians" (Online). New England Journal of Medicine. NEJM.org. 361 (18): 1717–1720. doi:10.1056/NEJMp0907708. PMID 19846841. Retrieved 2010-12-06.

[autogenerated1-20] GlaxoSmithKline and Sepracor Inc. announce international alliance for commercialisation of Lunivia

[21] COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USEm SUMMARY OF POSITIVE OPINION for LUNIVIA – European Medicines Agency/Committee for Medicinal Products for Human Use, 23 Oct 2010

[22] Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia (eszopiclone) – European Medicines Agency, 15 May 2009

[23] Data exclusivity and definition of a new active substance: suspension of generic escitalopram-containing medicines by CHMP – Bird and Bird Commercial Law 23 Apr 2010

v t e Insomnia pharmacotherapies

GABA_AR PAMs	Benzodiazepines: Brotizolam Cinolazepam Climazolam Clorazepate Doxefazepam Estazolam Etizolam Flunitrazepam Flurazepam Flutoprazepam Haloxazolam Loprazolam Lormetazepam Midazolam Nimetazepam Nitrazepam Quazepam Temazepam Triazolam Nonbenzodiazepines/Z-drugs: Eszopiclone Zaleplon Zolpidem Zopiclone Others: Alcohols (e.g., ethchlorvynol, amylene hydrate, ethanol) Barbiturates (e.g., amobarbital, pentobarbital, phenobarbital, secobarbital) Bromides (e.g., potassium bromide, sodium bromide) Carbamates (e.g., meprobamate) Chloral hydrate Clomethiazole Kava Paraldehyde Piperidinediones (e.g., glutethimide) Quinazolinones (e.g., methaqualone) Sulfonmethane Valerian

Antihistamines (H₁R inverse agonists)	Alimemazine Captodiame Dimenhydrinate Diphenhydramine Doxylamine Etodroxizine Hydroxyzine Methapyrilene Pheniramine Phenyltoloxamine Pimethixene Promethazine Propiomazine Pyrilamine

OXR antagonists	Almorexant^§ Filorexant^§ Lemborexant^§ SB-649,868^§ Suvorexant

MTR agonists	Agomelatine Melatonin Ramelteon Tasimelteon

Miscellaneous	Antipsychotics (e.g., quetiapine, olanzapine, chlorpromazine) Ashwagandha Benzoctamine Cannabinoids (e.g., cannabis, dronabinol (THC), nabilone) Chamomile Fenadiazole Gabapentinoids (e.g., gabapentin, pregabalin) Hops Lavender Menthyl isovalerate Niaprazine Opioids (e.g., hydrocodone, oxycodone, morphine) Passion flower Phenibut Scopolamine Serotonin precursors (tryptophan, 5-HTP) Sodium oxybate (GHB) Sympatholytics (e.g., clonidine, guanfacine) TCAs (e.g., amitriptyline, doxepin, trimipramine) TeCAs (e.g., mirtazapine) Theanine Trazodone Valnoctamide

v t e GABA_A receptor positive allosteric modulators

Alcohols	Brometone Butanol Chloralodol Chlorobutanol (cloretone) Ethanol (drinking alcohol) Ethchlorvynol Isobutanol Isopropanol Menthol Methanol Methylpentynol Pentanol Petrichloral Propanol tert-Butanol (2M2P) tert-Pentanol (2M2B) Tribromoethanol Trichloroethanol Triclofos Trifluoroethanol

Barbiturates	(-)-DMBB Allobarbital Alphenal Amobarbital Aprobarbital Barbexaclone Barbital Benzobarbital Benzylbutylbarbiturate Brallobarbital Brophebarbital Butabarbital/Secbutabarbital Butalbital Buthalital Butobarbital Butallylonal Carbubarb CP-1414S Crotylbarbital Cyclobarbital Cyclopentobarbital Difebarbamate Enallylpropymal Ethallobarbital Eterobarb Febarbamate Heptabarb Heptobarbital Hexethal Hexobarbital Metharbital Methitural Methohexital Methylphenobarbital Narcobarbital Nealbarbital Pentobarbital Phenallymal Phenobarbital Phetharbital Primidone Probarbital Propallylonal Propylbarbital Proxibarbital Reposal Secobarbital Sigmodal Spirobarbital Talbutal Tetrabamate Tetrabarbital Thialbarbital Thiamylal Thiobarbital Thiobutabarbital Thiopental Thiotetrabarbital Valofane Vinbarbital Vinylbital

Benzodiazepines	2-Oxoquazepam 3-Hydroxyphenazepam Adinazolam Alprazolam Arfendazam Avizafone Bentazepam Bretazenil Bromazepam Brotizolam Camazepam Carburazepam Chlordiazepoxide Ciclotizolam Cinazepam Cinolazepam Clazolam Climazolam Clobazam Clonazepam Clonazolam Clorazepate Clotiazepam Cloxazolam Cyprazepam Delorazepam Demoxepam Diazepam Diclazepam Doxefazepam Elfazepam Estazolam Ethyl carfluzepate Ethyl dirazepate Ethyl loflazepate Etizolam EVT-201 FG-8205 Fletazepam Flubromazepam Flubromazolam Fludiazepam Flunitrazepam Flurazepam Flutazolam Flutemazepam Flutoprazepam Fosazepam Gidazepam Halazepam Haloxazolam Iclazepam Imidazenil Irazepine Ketazolam Lofendazam Lopirazepam Loprazolam Lorazepam Lormetazepam Meclonazepam Medazepam Menitrazepam Metaclazepam Mexazolam Midazolam Motrazepam N-Desalkylflurazepam Nifoxipam Nimetazepam Nitrazepam Nitrazepate Nitrazolam Nordazepam Nortetrazepam Oxazepam Oxazolam Phenazepam Pinazepam Pivoxazepam Prazepam Premazepam Proflazepam Pyrazolam QH-II-66 Quazepam Reclazepam Remimazolam Rilmazafone Ripazepam Ro48-6791 Ro48-8684 SH-053-R-CH3-2′F Sulazepam Temazepam Tetrazepam Tolufazepam Triazolam Triflubazam Triflunordazepam (Ro5-2904) Tuclazepam Uldazepam Zapizolam Zolazepam Zomebazam

Carbamates	Carisbamate Carisoprodol Clocental Cyclarbamate Difebarbamate Emylcamate Ethinamate Febarbamate Felbamate Hexapropymate Lorbamate Mebutamate Meprobamate Nisobamate Pentabamate Phenprobamate Procymate Styramate Tetrabamate Tybamate

Flavonoids	6-Methylapigenin Ampelopsin (dihydromyricetin) Apigenin Baicalein Baicalin Catechin EGC EGCG Hispidulin Linarin Luteolin Rc-OMe Skullcap constituents (e.g., baicalin) Wogonin

Imidazoles	Etomidate Metomidate Propoxate

Kava constituents	10-Methoxyyangonin 11-Methoxyyangonin 11-Hydroxyyangonin Desmethoxyyangonin 11-Methoxy-12-hydroxydehydrokavain 7,8-Dihydroyangonin Kavain 5-Hydroxykavain 5,6-Dihydroyangonin 7,8-Dihydrokavain 5,6,7,8-Tetrahydroyangonin 5,6-Dehydromethysticin Methysticin 7,8-Dihydromethysticin Yangonin

Monoureides	Acecarbromal Apronal (apronalide) Bromisoval Carbromal Capuride Ectylurea

Neuroactive steroids	Acebrochol Allopregnanolone (SAGE-547) Alfadolone Alfaxalone Anabolic steroids 3α-Androstanediol Androstenol Androsterone Cholesterol DHDOC 3α-DHP 5α-DHP 5β-DHP DHT Etiocholanolone Ganaxolone Hydroxydione Minaxolone Org 20599 Org 21465 P1-185 Pregnanolone (eltanolone) Progesterone Renanolone SAGE-105 SAGE-217 SAGE-324 SAGE-516 SAGE-689 SAGE-872 Testosterone THDOC

Nonbenzodiazepines	β-Carbolines: Abecarnil Gedocarnil Harmane SL-651,498 ZK-93423; Cyclopyrrolones: Eszopiclone Pagoclone Pazinaclone Suproclone Suriclone Zopiclone; Imidazopyridines: Alpidem DS-1 Necopidem Saripidem Zolpidem; Pyrazolopyrimidines: Divaplon Fasiplon Indiplon Lorediplon Ocinaplon Panadiplon Taniplon Zaleplon; Others: Adipiplon CGS-8216 CGS-9896 CGS-13767 CGS-20625 CL-218,872 CP-615,003 CTP-354 ELB-139 GBLD-345 JM-1232 L-838,417 Lirequinil (Ro41-3696) NS-2664 NS-2710 NS-11394 Pipequaline ROD-188 RWJ-51204 SB-205,384 SX-3228 TGSC01AA TP-003 TPA-023 TP-13 U-89843A U-90042 Viqualine Y-23684

Phenols	Fospropofol Propofol Thymol

Piperidinediones	Glutethimide Methyprylon Piperidione Pyrithyldione

Pyrazolopyridines	Cartazolate Etazolate ICI-190,622 Tracazolate

Quinazolinones	Afloqualone Cloroqualone Diproqualone Etaqualone Mebroqualone Mecloqualone Methaqualone Methylmethaqualone Nitromethaqualone SL-164

Volatiles/gases	Acetone Acetophenone Acetylglycinamide chloral hydrate Aliflurane Benzene Butane Butylene Centalun Chloral Chloral betaine Chloral hydrate Chloroform Cryofluorane Desflurane Dichloralphenazone Dichloromethane Diethyl ether Enflurane Ethyl chloride Ethylene Fluroxene Gasoline Halopropane Halothane Isoflurane Kerosine Methoxyflurane Methoxypropane Nitric oxide Nitrogen Nitrous oxide Norflurane Paraldehyde Propane Propylene Roflurane Sevoflurane Synthane Teflurane Toluene Trichloroethane (methyl chloroform) Trichloroethylene Vinyl ether

Others/unsorted	3-Hydroxybutanal α-EMTBL AA-29504 Avermectins (e.g., ivermectin) Bromide compounds (e.g., lithium bromide, potassium bromide, sodium bromide) Carbamazepine Chloralose Chlormezanone Clomethiazole DEABL Dihydroergolines (e.g., dihydroergocryptine, dihydroergosine, dihydroergotamine, ergoloid (dihydroergotoxine)) DS2 Efavirenz Etazepine Etifoxine Fenamates (e.g., flufenamic acid, mefenamic acid, niflumic acid, tolfenamic acid) Fluoxetine Flupirtine Hopantenic acid Lanthanum Lavender oil Lignans (e.g., 4-O-methylhonokiol, honokiol, magnolol, obovatol) Loreclezole Menthyl isovalerate (validolum) Monastrol Niacin Nicotinamide (niacinamide) Org 25,435 Phenytoin Propanidid Retigabine (ezogabine) Safranal Seproxetine Stiripentol Sulfonylalkanes (e.g., sulfonmethane (sulfonal), tetronal, trional) Terpenoids (e.g., borneol) Topiramate Valerian constituents (e.g., isovaleric acid, isovaleramide, valerenic acid, valerenol) Unsorted benzodiazepine site PAMs: MRK-409 (MK-0343) TCS-1105 TCS-1205

See also: GABAergics

匿名

検索

案内

案内

eszopiclone